Please upgrade your browser.
Just initiating a search on the clinicaltrials.gov site (a service of the U.S. National Institutes of Health) raises numerous questions for the lay person...
WSJ: Next year’s enormous price increases are merely the latest expression of ObamaCare’s underlying problems, and the dysfunction is undermining the health security of Americans who lack employer coverage.
The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.
Articles include: Rebuilding the treatment paradigm with new pivotal trial data; Statins and targeted therapy
Positive progression-free survival data in patients with previously untreated advanced Renal Cell Carcinoma
Research has associated obesity as a factor that puts people at greater risk for cancer. This includes an increased risk for kidney cancer for people who are obese. Interestingly, however, once you have kidney cancer if you are obese research has shown that you may live up to 9 months longer...
Eisai Co., Ltd. announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.
Immunotherapy seeks to expose tumours to the cancer-killing power of the human immune system. It was declared “Breakthrough of the Year” by the journal Science in December 2013.
Arginase is an enzyme in myeloid-derived suppressor cells (MDSCs), which prevents T-cell and natural killer (NK) cell activation in tumors.
The new dosage regimen is for 240mg IV every 2 weeks until disease progression or intolerable toxicity for renal cell carcinoma...
|Powered by NeonCRM|